Do you want to read an article? Please log in or register.
Central retinal artery occlusion - a new, provisional treatment approach
Retinal Diseases
Related content
Retinal Diseases
Standardized Approach to Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Soft-Tissue Fillers: EYE-CODE
J Am Acad Dermatol
Barbarino S, Banker T, Fezza J
doi: 10.1016/j.jaad.2020.12.047
Ambient Air Pollution and the Risk of Central Retinal Artery Occlusion
Ophthalmology.
Cheng HC, Pan RH, Yeh HJ, Lai KR, Yen MY, Chan CL, Wang AG
doi: 10.1016/
Retinal Diseases
Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion
Am J Ophthalmol.
Nicholson L, Vazquez-Alfageme C, Patrao NV, Triantafyllopolou I, Bainbridge JW, Hykin PG, Sivaprasad S
doi: 10.1016/j.ajo.2017.07.015.
Macular DiseasesRetinal DiseasesFurther Publications
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.
doi: 10.1001/jamaophthalmol.2021.4395
Macular DiseasesRetinal Diseases
Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial
JAMA Ophthalmol.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Chan CK, SCORE2 Investigator Group.
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal Diseases
Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept
BMC Ophthalmol
Zhang Q, Hou Y, Cao X, Zhang R, Liu Y, Wei C, Wu C, Mei L, Zhang P
doi: 10.1186/s12886-021-02174-0
COMMENTED
Retinal Diseases
Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Gale R, Gill C, Pikoula M, Lee AY, Hanson RLW, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Database Users Group.
doi: 10.1136/bjophthalmol-2020-317306
Macular DiseasesRetinal Diseases
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial
Ophthalmol Retina.
Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) Study Group.
doi: 10.1016/j.oret.2019.12.019.
Macular Diseases
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study
JAMA Ophthalmol.
Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group
doi: 10.1001/jamaophthalmol.